|Bid||20.65 x 900|
|Ask||20.70 x 900|
|Day's Range||19.70 - 20.93|
|52 Week Range||19.70 - 61.57|
|Beta (5Y Monthly)||0.64|
|PE Ratio (TTM)||51.41|
|Earnings Date||Feb 22, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.18|
The partnership makes it possible for patients with specific biomarkers to get early supportFT. MYERS, FL / ACCESSWIRE / January 24, 2022 / NeoGenomics, Inc.
MYERS, FL / ACCESSWIRE / January 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has received the CE mark for its RaDaR™ assay for the detection of molecular residual disease (MRD) and recurrence, having met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC).
Office leasing activity continues in the Scottsdale area despite the continuing pandemic. One of the new tenants at SkySong is NeoGenomics Inc., a publicly-traded cancer research firm.